Literature DB >> 11712881

Diagnosis and treatment of perianal fistulas in Crohn disease.

D A Schwartz1, J H Pemberton, W J Sandborn.   

Abstract

Perianal fistulas occur in up to 43% of patients with Crohn disease. Diagnostic evaluation to determine the location and type of fistulas and the presence or absence of rectal inflammation is required. A combined medical and surgical approach to the management of such patients is the optimal treatment plan. Perianal abscesses must be drained. Superficial, low transsphincteric, and low intersphincteric fistulas are usually treated with fistulotomy and antibiotics. High transsphincteric, suprasphincteric, and extrasphincteric fistulas are usually treated with noncutting setons, antibiotics, and azathioprine or 6-mercaptopurine and, in many cases, infliximab.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11712881     DOI: 10.7326/0003-4819-135-10-200111200-00011

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  36 in total

1.  Outcome of patients with nonstenotic, nonfistulizing Crohn's disease.

Authors:  Pilar Nos; Vicente Garrigues; Guillermo Bastida; Nuria Maroto; Marta Ponce; Julio Ponce
Journal:  Dig Dis Sci       Date:  2004 Nov-Dec       Impact factor: 3.199

Review 2.  Evaluation of perianal fistulas in patients with Crohn's disease.

Authors:  Jennifer Jones; William Tremaine
Journal:  MedGenMed       Date:  2005-05-18

Review 3.  How should complex perianal Crohn's disease be treated in the Remicade era.

Authors:  Lisa S Poritz
Journal:  J Gastrointest Surg       Date:  2006-05       Impact factor: 3.452

Review 4.  Antibiotics and probiotics in treatment of inflammatory bowel disease.

Authors:  Paolo Gionchetti; Fernando Rizzello; Karen-M Lammers; Claudia Morselli; Lucia Sollazzi; Samuel Davies; Rosy Tambasco; Carlo Calabrese; Massimo Campieri
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

Review 5.  Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution.

Authors:  Annabel Kuek; Brian L Hazleman; Andrew J K Ostör
Journal:  Postgrad Med J       Date:  2007-04       Impact factor: 2.401

Review 6.  Evidence for the involvement of infectious agents in the pathogenesis of Crohn's disease.

Authors:  Gert De Hertogh; Jeroen Aerssens; Karen P Geboes; Karel Geboes
Journal:  World J Gastroenterol       Date:  2008-02-14       Impact factor: 5.742

Review 7.  Therapy for Crohn's Disease: a Review of Recent Developments.

Authors:  Gregory J Eustace; Gil Y Melmed
Journal:  Curr Gastroenterol Rep       Date:  2018-04-05

Review 8.  Perianal Crohn's disease: is there something new?

Authors:  Cesare Ruffolo; Marilisa Citton; Marco Scarpa; Imerio Angriman; Marco Massani; Ezio Caratozzolo; Nicolò Bassi
Journal:  World J Gastroenterol       Date:  2011-04-21       Impact factor: 5.742

9.  Long-term success rate after surgical treatment of anorectal and rectovaginal fistulas in Crohn's disease.

Authors:  Thorsten Löffler; Thilo Welsch; Stefanie Mühl; Ulf Hinz; Jan Schmidt; Peter Kienle
Journal:  Int J Colorectal Dis       Date:  2009-01-27       Impact factor: 2.571

10.  Adalimumab for the treatment of fistulas in patients with Crohn's disease.

Authors:  J-F Colombel; D A Schwartz; W J Sandborn; M A Kamm; G D'Haens; P Rutgeerts; R Enns; R Panaccione; S Schreiber; J Li; J D Kent; K G Lomax; P F Pollack
Journal:  Gut       Date:  2009-02-06       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.